TechSeeker Profile

PharmaEngine
Profile last edited on: 7/9/2013

Biopharmaceuticals & Biotherapeutics
TS Type
N/A
Status
Year Founded
2003
Last Involved Year
2011

Key People / Management

Location Information

16F-2, No.237, Sung-Chiang Road, Jhongshan District
Taipei, TW 104
   886-2-25158228
   www.pharmaengine.com

Public Profile

PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003 principally engaged in the research and development of anticancer drugs. The Company's anticancer drugs are used in the treatment of pancreas cancer, gastric cancer, large intestine and rectal cancer, lung cancer, as well as cerebral cancer. As of December 31, 2011, the Company obtained its major revenue from product warranty transfer fee.PharmaEngine adopts the business model of “no research, development only” and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. The lead project PEP02 (nanoliposomal irinotecan, aka MM-398) which was licensed to Merrimack Pharmaceuticals, Inc., (Cambridge, MA, USA), is in a global phase III study for the treatment of metastatic pancreatic cancer; the second is PEP503 (crystalline hafnium oxide, aka NBTXR3) from Nanobiotix, Inc. (Paris, France); and the third was a collaboration with Guangzhou BeBetter Medicine Technology, Co., Ltd. (Guangzhou, China).

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
Taiwan
Employment
17
Revenue
$0.0B
Public/Private
Publicly Traded
Stock Info
Taiwan : 4162
Received SBIR $$
No

SBIR firms in the news

There are no news available.